These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24963517)

  • 41. Combining immunotherapy with radiation for the treatment of glioblastoma.
    Chow KK; Hara W; Lim M; Li G
    J Neurooncol; 2015 Jul; 123(3):459-64. PubMed ID: 25877468
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trials and tribulations of cancer immunotherapy: the dendritic cell vaccine shows promise in a phase I glioblastoma multiforme trial.
    Gürsel DB; Schlaff CD; Boockvar JA
    Neurosurgery; 2012 Dec; 71(6):N19-21. PubMed ID: 23160396
    [No Abstract]   [Full Text] [Related]  

  • 43. Glioblastoma multiforme: evidence-based approach to therapy.
    Nicholas MK
    Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S23-7. PubMed ID: 18076314
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The current and future aspects of glioblastoma: Immunotherapy a new hope?
    Patel V; Shah J
    Eur J Neurosci; 2021 Aug; 54(3):5120-5142. PubMed ID: 34107127
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanisms of immunomodulation in human glioblastoma.
    Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
    Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients.
    Van Gool SW; Van de Vliet P; Kampers LFC; Kosmal J; Sprenger T; Reich E; Schirrmacher V; Stuecker W
    Methods Cell Biol; 2024; 183():51-113. PubMed ID: 38548421
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stemline's synthetic multi-peptide cancer vaccine enters Phase 2.
    Riedmann EM
    Hum Vaccin Immunother; 2014; 10(6):1430. PubMed ID: 25396232
    [No Abstract]   [Full Text] [Related]  

  • 48. Heat shock proteins in glioblastomas.
    Yang I; Fang S; Parsa AT
    Neurosurg Clin N Am; 2010 Jan; 21(1):111-23. PubMed ID: 19944971
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma.
    Sonabend AM; Dana K; Lesniak MS
    Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S45-50. PubMed ID: 18076318
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peptide vaccine therapy for childhood gliomas.
    Pollack IF; Jakacki RI; Butterfield LH; Okada H
    Neurosurgery; 2013 Aug; 60 Suppl 1():113-9. PubMed ID: 23839362
    [No Abstract]   [Full Text] [Related]  

  • 51. [Immunotherapy for malignant glioblastoma].
    Nose T; Nakagawa K
    No Shinkei Geka; 1995 Mar; 23(3):195-206. PubMed ID: 7700486
    [No Abstract]   [Full Text] [Related]  

  • 52. [A trial of rabies vaccine treatment of patients with glioblastoma multiforme].
    Filipov FV
    Zh Vopr Neirokhir Im N N Burdenko; 1988; (3):38-40. PubMed ID: 2842989
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [CTL precursor-oriented peptide vaccine therapy for malignant glioma].
    Yajima N; Yamanaka R; Tanaka R; Shigemori M; Mine T; Itoh K
    Nihon Rinsho; 2005 Sep; 63 Suppl 9():582-7. PubMed ID: 16201585
    [No Abstract]   [Full Text] [Related]  

  • 54. Recent advances in therapy for glioblastoma.
    Clarke J; Butowski N; Chang S
    Arch Neurol; 2010 Mar; 67(3):279-83. PubMed ID: 20212224
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Our failure to advance new treatments for glioma to market.
    Sampson JH; Kaminski TJ; Schulman KA
    J Neurosurg; 2011 Aug; 115(2):245-7; discussion 247. PubMed ID: 21568655
    [No Abstract]   [Full Text] [Related]  

  • 56. The intersection between genetic engineering and immunotherapy: taking a BiTE out of glioblastoma.
    Njoku I; Boockvar JA
    Neurosurgery; 2013 Jun; 72(6):N16-7. PubMed ID: 23685511
    [No Abstract]   [Full Text] [Related]  

  • 57. Cell fusion technology vaccine tested in kidney cancer clinical trial.
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):620. PubMed ID: 12503204
    [No Abstract]   [Full Text] [Related]  

  • 58. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination.
    Wheeler CJ; Das A; Liu G; Yu JS; Black KL
    Clin Cancer Res; 2004 Aug; 10(16):5316-26. PubMed ID: 15328167
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The progress of immunotherapy for glioblastoma.
    Zhou Q; Wang Y; Ma W
    Hum Vaccin Immunother; 2015; 11(11):2654-8. PubMed ID: 26308501
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increasing immunogenicity of cancer vaccines to improve their clinical outcome.
    Parmiani G; Cimminiello C; Maccalli C
    Expert Rev Vaccines; 2013 Oct; 12(10):1111-3. PubMed ID: 24124873
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.